[{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Seroba Life Sciences","pharmaFlowCategory":"D","amount":"$8.3 million","upfrontCash":"Undisclosed","newsHeadline":"Shorla Nabs $8.3M to Bring Improved Cancer Meds to the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"IRELAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Eversana","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection for the Treatment of T-cell Leukemia Across the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Shorla Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"IRELAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Kurma Partners\u2019 Growth Opportunities Fund","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"IRELAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Therakind","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shorla Oncology Announces FDA Filing Acceptance of New Drug Application for Novel Formulation to Treat Breast and Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shorla Oncology & EVERSANA Announce U.S. Commercial Launch of FDA-Approved JYLAMVO, the First and Only Oral Methotrexate Solution Approved in the U.S. for Adults","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shorla Oncology Gets FDA Approval for TEPYLUTE for Breast and Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"}]
Find Clinical Drug Pipeline Developments & Deals by Shorla Oncology
SH-201 is the first palatable oral liquid of the related chemotherapeutic agent in the U.S. SH-201 is an oral liquid treatment that slows or stops the growth of certain forms of leukemia (such as acute lymphoblastic leukemia and chronic myeloid leukemia) and other cancers.
SH-105 is a ready-to-dilute form of a well-established drug that has been used as a freeze-dried powder. It is being evaluated for the treatment of breast and ovarian cancer.
Jylamvo (methotrexate) is a DHFR inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of acute lymphoblastic leukemia in adults.
Through the acquisition, Shorla gains Jylamvo, an oncology and autoimmune drug and easy-to-administer, sweet tasting oral methotrexate solution that eliminates the need for crushing or splitting pills, or compounding into a liquid formulation, for the US market.
The financing will be used to accelerate the growth of its oncology portfolio by advancing its pipeline, including SH-105, bringing therapies to market that will address drug shortages, and improving the preparation and application of oncology medication.
Under the agreement, Shorla will obtain an exclusive license from the developer to register and commercialize PIP-101, the first palatable oral solution of the related chemotherapeutic agent in the U.S. that slows or stops the growth of certain forms of leukemia.
Nelarabine Injection is a nucleoside metabolic inhibitor indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older.
The funding will support the advancement of the product pipeline, along with expansion of technical and commercial operations in both Ireland and the US.